Cargando…
PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study
BACKGROUND: Statin treatment and variants in the gene encoding HMG-CoA reductase are associated with reductions in both the concentration of LDL cholesterol and the risk of coronary heart disease, but also with modest hyperglycaemia, increased bodyweight, and modestly increased risk of type 2 diabet...
Ejemplares similares
-
Osteoprotegerin concentration and risk of cardiovascular outcomes in nine general population studies: Literature-based meta-analysis involving 26,442 participants
por: Tschiderer, Lena, et al.
Publicado: (2017) -
FURIN Expression in Vascular Endothelial Cells Is Modulated by a Coronary Artery Disease–Associated Genetic Variant and Influences Monocyte Transendothelial Migration
por: Yang, Xu, et al.
Publicado: (2020) -
Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9
por: Schmidt, Amand F., et al.
Publicado: (2019) -
Associations of Serum Dickkopf‐1 and Sclerostin With Cardiovascular Events: Results From the Prospective Bruneck Study
por: Klingenschmid, Gerhard, et al.
Publicado: (2020) -
Sex-Specific Association of the Putative Fructose Transporter SLC2A9 Variants With Uric Acid Levels Is Modified by BMI
por: Brandstätter, Anita, et al.
Publicado: (2008)